Notice2022-26430
Prospective Grant of an Exclusive Patent License: Use and Development of RAB13 and NET1 Targeting Antisense Oligonucleotides in the Treatment of Cancer
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
December 6, 2022
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the U.S. Patents and Patent Applications listed in the Supplementary Information section of this notice to Drug Development and Filing Consulting, LLC located in Maryland, USA.
Full Text
<html>
<head>
<title>Federal Register, Volume 87 Issue 233 (Tuesday, December 6, 2022)</title>
</head>
<body><pre>
[Federal Register Volume 87, Number 233 (Tuesday, December 6, 2022)]
[Notices]
[Page 74648]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2022-26430]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive Patent License: Use and
Development of RAB13 and NET1 Targeting Antisense Oligonucleotides in
the Treatment of Cancer
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Cancer Institute, an institute of the National
Institutes of Health, Department of Health and Human Services, is
contemplating the grant of an Exclusive Patent License to practice the
inventions embodied in the U.S. Patents and Patent Applications listed
in the Supplementary Information section of this notice to Drug
Development and Filing Consulting, LLC located in Maryland, USA.
DATES: Only written comments and/or applications for a license which
are received by the National Cancer Institute's Technology Transfer
Center on or before December 21, 2022 will be considered.
ADDRESSES: Requests for copies of the patent application, inquiries,
and comments relating to the contemplated an Exclusive Patent License
should be directed to: Suna Gulay French, Technology Transfer Manager,
Telephone: (240)-276-7424; Email: <a href="/cdn-cgi/l/email-protection#2e5d5b404f00495b424f576e40474600494158"><span class="__cf_email__" data-cfemail="84f7f1eae5aae3f1e8e5fdc4eaedecaae3ebf2">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION:
Intellectual Property
1. United States Provisional Patent Application No. 62/966,204,
filed January 27, 2020 and entitled ``RAB13 and NET1 Antisense
Oligonucleotides to Treat Metastatic Cancer'' [HHS Ref. No. E-041-2020-
0-US-01];
2. PCT Patent Application No. PCT/US2021/015053, filed January 26,
2021 and entitled ``RAB13 and NET1 Antisense Oligonucleotides to Treat
Metastatic Cancer'' [HHS Ref. No. E-041-2020-0-PCT-02]; and
3. United States Patent Application No. 17/792,507, filed July 13,
2022 and entitled ``Antisense Oligos that Block Cancer Cell Migration
and Invasion'' [HHS Ref. No. E-041-2020-0-US-03].
The patent rights in these inventions have been assigned and/or
exclusively licensed to the government of the United States of America.
The prospective exclusive license territory may be the United
States only and the field of use may be limited to: ``Use and
development of RAB13 and NET1 targeting antisense oligonucleotides in
treatment of breast cancer, ovarian cancer, cervical cancer and head
and neck cancer in humans.''
This technology discloses RAB13 and NET1 targeting antisense
oligonucleotides (ASOs) for use in targeted cancer therapy. These ASOs
bind to the 3'-untranslated regions of RAB13 and NET1 mRNAs and prevent
the localization of these mRNAs to cellular protrusions involved in
motility. These ASOs reduce cell motility and migration in vitro. Due
to this reduction in cell motility and migration, these ASOs are
expected to have uses in the treatment of metastatic cancers.
This notice is made in accordance with 35 U.S.C. 209 and 37 CFR
part 404. The prospective exclusive license will be royalty bearing,
and the prospective exclusive license may be granted unless within
fifteen (15) days from the date of this published notice, the National
Cancer Institute receives written evidence and argument that
establishes that the grant of the license would not be consistent with
the requirements of 35 U.S.C. 209 and 37 CFR part 404.
In response to this Notice, the public may file comments or
objections. Comments and objections, other than those in the form of a
license application, will not be treated confidentially, and may be
made publicly available.
License applications submitted in response to this Notice will be
presumed to contain business confidential information and any release
of information in these license applications will be made only as
required and upon a request under the Freedom of Information Act, 5
U.S.C. 552.
Dated: November 30, 2022.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer
Institute.
[FR Doc. 2022-26430 Filed 12-5-22; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on December 6, 2022.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.